openPR Logo
Press release

Knowbella Files Form 1-A with the U.S. SEC to Launch Regulation A+ STO

06-14-2018 09:06 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Knowbella Tech

Helix, "The Currency of Science?"

Helix, "The Currency of Science?"

One of the first to file a regulated Initial Coin Offering (ICO) with the U.S. Securities and Exchange Commission.

Cincinnati, Ohio – June 13, 2018 - Knowbella Helix Inc. (“Knowbella” or the “Company”), a scientific collaboration company, today announced that on June 7, 2018, it filed an Offering Statement on Form 1-A with the Securities and Exchange Commission to launch a Regulation A+ securities token offering (STO) in the United States. The Offering Statement relates to an offering of $50 million of Helix™ tokens under Tier 2 of Regulation A+.

“Until now almost no other firm has launched an STO, or what some might call, a regulated ICO, using an SEC-compliant Reg A+,” said Mark Pohlkamp, CEO. “Knowbella aims to be among the first to use this innovative model to launch its Helix™ token, “The Currency of Science™”.

The net proceeds of this offering will be used primarily to launch a blockchain-enabled open science crowdsourcing platform (the Knowbella Platform) that aims to unlock up to $4 trillion of idle intellectual property. Collaborating scientists will be rewarded Helix for collaborating on the Knowbella Platform. Of particular interest is enabling the underserved scientists in Africa, Asia, and Latin America to collaborate.

Utilizing Regulation A+, Knowbella plans to make its Helix™ tokens available to anyone interested in participating in the open science effort. Typically, in the U.S., only accredited investors qualify to invest in early stage companies. With Regulation A+ approval, Knowbella intends to provide non-accredited investors the opportunity to participate too.

Pohlkamp continued, “Regulation A+ allows us to advertise and reach many who may have an interest in our scientific platform and business. An approved STO will allow us to offer participants an equity opportunity in our Company in the form of Helix™ tokens. Helix™ may be considered by some to be a cryptocurrency as we intend it to be traded on an SEC-compliant exchange.”

Knowbella has tied its Class H Common Shares to the Helix™. This means that under certain circumstances, if the Company experiences certain liquidity events, the holders of Helix™ gain certain equity in the Company while keeping their Helix™ tokens.

Knowbella has engaged Keating Muething & Klekamp PLL as its legal advisors for the offering.

Knowbella plans to “test the waters” to gauge market demand for its proposed Regulation A+ offering prior to qualification of its offering statement by the SEC. No money or consideration is being solicited by the information in this press release or any other communication and, if sent, money will not be accepted and will be promptly returned. No offer by a potential investor to buy our securities can be accepted and, if made, any such offer can be withdrawn before qualification of this offering by the SEC. A potential investor’s indication of interest does not create a commitment to purchase the securities we are offering. Any such indication of interest may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance is given and all other requirements to accept an investment from a potential investor are met after the offering qualification date.

The offering, after qualification by the SEC, will be made only by means of an Offering Circular. Any information in this press release or any other communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification for sale as provided in Regulation A+ in any such state or jurisdiction.

You may obtain a copy of the Preliminary Offering Circular and the Offering Statement in which such Preliminary Offering Circular was filed with the SEC by visiting: https://www.sec.gov/Archives/edgar/data/1742956/000095012318006161/d553677dpartiiandiii.htm

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", “plans”, “aims”, "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to various risk factors, which are discussed in the Company's Preliminary Offering Circular, which is filed with the SEC on www.sec.gov. While the Company may elect to, it does not undertake to update this information at any particular time.

ABOUT:

Knowbella's mission is crowdsourcing the global scientific community around orphan and dormant intellectual properties to advance science and generate a public good. The freely available Knowbella Platform that will result from a successful Initial Coin Offering (ICO) will enable scientists to collaborate around advancing technologies. Scientists will be rewarded for their conduct of science within the Platform with Helix™, “The Currency of Science™.”

CONTACT:

Mark Pohlkamp, CEO
+1.513.260.4400
https://Knowbella.Tech
Mark@Knowbella.Tech
Twitter: @Knowbella
Telegram: https://t.me/knowbella
PO Box 30085
Cincinnati, OH 45230

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Knowbella Files Form 1-A with the U.S. SEC to Launch Regulation A+ STO here

News-ID: 1081426 • Views: 1255

More Releases from Knowbella Tech

Knowbella Tech Selected as Finalist for 2019 SXSW Pitch
Knowbella Tech to showcase the Knowbella Platform™ in the blockchain category Cincinnati, OH — January 9th, 2019 — Knowbella Tech, an open science collaboration platform company, was selected as a finalist in the Blockchain category for the 11th annual SXSW Pitch® (formerly SXSW Accelerator). SXSW Pitch is the marquee event of South by Southwest® (SXSW®) Conference & Festivals (March 8-17, 2019) Entrepreneurship & Startup Track, where leading startups from around
Knowbella Tech and doDOC™ Partner to Integrate doDOC™ Content Management Sys …
Innovative manuscript development tool to be integrated into scientific collaboration platform. Cincinnati, OH and Boston, MA – June 26, 2018 - Knowbella Tech LLC, a scientific collaboration platform company, and doDOC, a document creation and management tool company, have partnered. Knowbella Platform™ will freely provide its scientific users with the doDOC scientific manuscript development tool. According to Mark Pohlkamp, CEO of Knowbella Tech, “The Knowbella Tech scientific collaboration platform is being
Knowbella Tech Announces Intent to Conduct First Tier 2 Regulation A+ Initial Co …
Would be one of the first to file Initial Coin Offering to the US Securities and Exchange Commission. Cincinnati, Ohio – February 28, 2018 - Knowbella Tech LLC, a scientific collaboration company, announces it intends to file an offering statement with the United States Securities and Exchange Commission (SEC) to conduct a $50 million Regulation A+ securities offering in the United States. “Until now no initial coin offering, or ICO, has raised

All 4 Releases


More Releases for Helix

Detailed Market Study on Myc Proto Oncogene Protein (Transcription Factor p64 or …
Based on Myc Proto Oncogene Protein H2 2017, a research study is published titled “Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) -Pipeline Review, H2 2017” and submitted recently with Market Research Hub (MRH). The report offers comprehensive insights on the pipeline review on Myc Proto Oncogene Protein H2 2017. According to the report, the target pipeline consists of 14 molecules
Global Linear DC Actuators Market 2017 - LINAK, Helix, Thomson, IAI
Apex Research, recently published a detailed market research study focused on the "Linear DC Actuators Market" across the global, regional and country level. The report provides 360° analysis of "Linear DC Actuators Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Linear DC Actuators industry, and estimates the future trend of Linear
Maxtena Launches New GPS Helix Antenna Tuning Kit
U.S. based Maxtena, a top developer and producer for innovative wireless solutions, have created the first GPS helix antenna tuning kit aimed at simplifying embedded antenna integrations. Maxtena designed the tuning kit to empower hardware developers working on devices requiring an embedded antenna configuration. The tuning kit allows for both quick and easy antenna selection and removes the need for a lengthy and costly custom antenna integration process. The use of
Helix Launches New Responsive Website
WEST MALLING, KENT, England, 22 August 2013 The range of web solutions offered by Helix Websites has expanded considerably in the last couple of years and their advanced new website provides a platform to showcase all the products and features they are able to offer including responsive design functionality. Their new mobile-ready site uses latest technologies, search engine optimization techniques, and design elements that Helix customers can expect in their
Harmonised GCP Training Courses Launched by Helix Research Center
Inspired by the initiative of Sponsors of ICH ( International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals of Human Use) Viz,European Agency for the Evaluation of Medicinal Products ( EMEA),Japanese Ministry of Health,Labour and Welfare (JMHLW) and the US Food and Drug Administration (USFDA) , the Co Sponsors;Viz ,the European Federation of Pharmaceutical Industries' Associations (EFPIA),the Japanese Pharmaceutical Manufacturers Association (JPMA),the Pharmaceutical Research and Manufacturers of
Helix Announces Research and Clinical Auditing Services Worldwide
Since Human Life is most precious and under no circumstances any kind of harm to Human Body and /or Mind are forgiven either on Moral or Legal grounds, any Healthcare or Clinical Research Services Provider must always strive hard to ensure Utmost Quality Services,Protection of Human Rights,Confidentiality of Medical Information ,Safety and well being of the Patients/Clinical Trial Subjects.More over,as Healthcare is included under 'Essential Services Act' in